← Every firm
Nostrum Laboratories, Inc. FDA Recalls
3 recalls on file across drugs, 0 of them Class I and 3 still open. This firm is not matched to a listed company.
Newest first
Class I is the FDA's most serious grade: a reasonable probability of serious harm or death.
| Product |
|---|
| Sucralfate Tablets, USP 1 gram, packaged in a) 100-count bottles NDC 29033-0003-01, and b) 500-count bottles, NDC 29033-Class IIJul 11, 2025CGMP Deviations: The recalling firm filed for Chapter 11 in |
| Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg, 100 Tablets per bottle, Rx Only, Manufactured by: NostrumClass IIJan 25, 2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) |
| Metformin Hydrochloride Extended-Release Tablets, USP, 750 mg, 100 tablets per bottle, Rx Only, Manufactured by: NostrumClass IIJan 4, 2021CGMP Deviations: detection of N-Nitrosodimethylamine (NDMA) |